Antimicrobial resistance and production of beta-lactamases in Bulgarian clinical isolatesMoraxella catarrhalis
One hundred and fifteen strains ofMoraxella catarrhalis from inpatients and healthy children were collected from 2000 to 2005. MICs to 17 antimicrobial agents from different groups were determined. High resistance rate to penicillin G, aminopenicillins and first generation cephalosporins (98.26%) was found. Susceptibility to cefuroxime, cefotaxime and ceftriaxone was from 86.08 to 97.40%. AllM. catarrhalis strains were susceptible to aminopenicillin/inhibitor combinations, ceftazidime, ceftibuten, ciprofloxacin and gentamicin. The susceptibility rates to azithromycin, clarithromycin, tetracycline and trimethoprim/sulfamethoxazole were reduced in range of 6–9%. Presence ofbro1 orbro2 genes was revealed in 113M. catarrhalis strains by PCR. The overall prevalence of the BRO-1 and BRO-2 enzymes was 92.92 and 7.08% respectively. MICs of Penicllin were significantly higher inbro1 positive isolates.
Key wordsMoraxella catarrhalis beta-lactamases bro PCR
Unable to display preview. Download preview PDF.
- Doern G.V., Brueggemann A.B., Pierce G., Hogan T., Holley H.P., Rauch A. (1996). Prevalence of antimicrobial resistance among 723 outpatient clinical isolates ofMoraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother., 40: 2884–2886.PubMedGoogle Scholar
- Jones M.E., Blosser-Middleton R.S., Critchley I.A., Karlowsky J.A., Thornsberry C., Sahm D.F. (2003).In vitro susceptibility ofStreptococcus pneumoniae, Haemophilus influenzae andMoraxella catarrhalis: a European multicenter study during 2000–2001. Clin. Microbiol. Infect., 9 (7): 590–599.CrossRefPubMedGoogle Scholar
- Melo-Cristino J., Santos L., Ramirez M., Grupo de Estudo Portugues de Bacterias Patogenicas Respiratorias (2006). Virato study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004. Rev. Port. Pneumol., 12 (1): 9–30.PubMedGoogle Scholar
- National Committee for Clinical Laboratory Standards (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4. National Committee for Clinical Laboratory Standards, 2006.Google Scholar
- Richter S.S., Winokur P.L., Brueggemann A.B., Huynh H.K., Rhomberg P.R., Wingert E.M., Doern G.V. (2000). Molecular characterization of the β-lactamases from clinical isolates ofMoraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994–1995 and 1997–1998. Antimicrob. Agents Chemother., 44: 444–446.CrossRefPubMedGoogle Scholar
- Wallace R.J., Steingrube V.A., Nash D.R., Hollis D., Flanagan C., Brown B.A., Labidi A., Weaver R. (1989). BRO β-lactamases ofBranhamella catarrhalis andMoraxella subgenusMoraxella, including evidence for chromosomal β-lactamase transfer by conjugation inB. catarrhalis, M. nonliquefaciens, andM. lacunata. Antimicrob. Agents Chemother., 33: 1845–1854.PubMedGoogle Scholar
- Zhanel G.G., Palatnick L., Nichol K.A., Low D.E., Hoban D.J. (2003). Antimicrobial resistance inHaemophilus influenzae andMoraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob. Agents Chemother., 47: 1875–1881.CrossRefPubMedGoogle Scholar